Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)
Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)
Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial
2021
Stem Cells Translational Medicine
10
9
1279
1287
5
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107732762&doi=10.1002%2fsctm.21-0046&partnerID=40&md5=197659d90f645ca5130e69fcf16b7b4d
Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia; Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Anesthesiology and Intensive Care Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Intensive Care Division, Universitas Indonesia Hospital, Depok, Indonesia; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan General Hospital, Jakarta, Indonesia; Directorate of Medical Services, Nursing and Supporting, Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Directorate of Human Resources Development, Education and Operational Sulianti Saroso Infection Disease Hospital, Jakarta, Indonesia; Department of Histology, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Department of Anatomy, Universitas Indonesia Fakultas Kedokteran, Jakarta, Indonesia; Installation of Innovation Management and Intellectual Property, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
One of the main causes of acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19) is cytokine storm, although the exact cause is still unknown. Umbilical cord mesenchymal stromal cells (UC-MSCs) influence proinflammatory T-helper 2 (Th2) cells to shift to an anti-inflammatory agent. To investigate efficacy of UC-MSC administration as adjuvant therapy in critically ill patients with COVID-19, we conducted a double-blind, multicentered, randomized controlled trial at four COVID-19 referral hospitals in Jakarta, Indonesia. This study included 40 randomly allocated critically ill patients with COVID-19; 20 patients received an intravenous infusion of 1 ? 106/kg body weight UC-MSCs in 100 ml saline (0.9%) solution (SS) and 20 patients received 100 ml 0.9% SS as the control group. All patients received standard therapy. The primary outcome was measured by survival rate and/or length of ventilator usage. The secondary outcome was measured by clinical and laboratory improvement, with serious adverse events. Our study showed the survival rate in the UC-MSCs group was 2.5 times higher than that in the control group (P?=.047), which is 10 patients and 4 patients in the UC-MSCs and control groups, respectively. In patients with comorbidities, UC-MSC administration increased the survival rate by 4.5 times compared with controls. The length of stay in the intensive care unit and ventilator usage were not statistically significant, and no adverse events were reported. The application of infusion UC-MSCs significantly decreased interleukin 6 in the recovered patients (P?=.023). Therefore, application of intravenous UC-MSCs as adjuvant treatment for critically ill patients with COVID-19 increases the survival rate by modulating the immune system toward an anti-inflammatory state. ? 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.
5' nucleotidase; azithromycin; C reactive protein; CD34 antigen; CD4 antigen; CD56 antigen; CD8 antigen; chemokine receptor CXCR3; D dimer; ferritin; fibrinogen; hemoglobin; interleukin 10; interleukin 6; lactic acid; leukemia inhibitory factor; oseltamivir; procalcitonin; Thy 1 membrane glycoprotein; vasculotropin; adjuvant therapy; adult; adult respiratory distress syndrome; Article; artificial ventilation; blood cell count; clinical article; clinical decision making; computer assisted tomography; controlled study; coronavirus disease 2019; critically ill patient; cytokine release syndrome; cytokine storm; double blind procedure; female; flow cytometry; fluid resuscitation; ground glass opacity; hematocrit; Horowitz index; human; hypotension; intensive care unit; length of stay; leukopen
John Wiley and Sons Ltd
21576564
34102020
Article
Q1
1781
1654